Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 15 from 10:20 a.m. to 10:50 a.m. The conference is being held at Le Parker Meridien Hotel in New York, New York. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.

To access the live webcast of Paratek's session, please visit http://wsw.com/webcast/wedbush33/prtk.  Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed in the investor section of http://www.paratekpharma.com for 90 days following the live presentation. About ParatekParatek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The Company’s lead product candidate, omadacycline, is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications. Paratek has completed Phase 3 development activities for omadacycline in CABP and ABSSSI and is preparing to submit marketing applications in the United States and European Union. Paratek has licensed rights for omadacycline to Zai Lab for the greater China region, and retains all remaining global rights.

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.  Paratek's second Phase 3 product candidate, sarecycline, is being developed by Allergan in the U.S. as a new once-daily oral therapy for the treatment of acne. Allergan has completed Phase 3 development activities for sarecycline and is preparing a new drug application for submission to the U.S. Food and Drug Administration. Paratek retains all ex-U.S. rights to sarecycline.  Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.  For more information, visit www.paratekpharma.com or follow @ParatekPharma on Twitter. 

CONTACTS:

Media Relations:		Investor Relations:
Michael Lampe		Hans Vitzthum
[phone]		LifeSci Advisors, LLC.
[e-mail]		212-915-2568